lungcancer - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Unmet needs and opportunities in non-small cell lung cancer

The use of checkpoint inhibitors is commonplace throughout the 8MM for patients who do not harbor actionable mutations. Credit: David A Litman/Shutterstock.